CONGRESS PROGRAM

Monday, 30 October

07:30	Registration
08:30	Session I: Opening
	08:30-08:35 Welcome to London and Introduction of Distinguished Speaker Julia Manning, Founding Director, 2020health, UK (Co-Chair) 08:35-08:50 Professor Richard Barker, OBE, Founding Director of the Centre for the Advancement of Sustainable Medical Innovation (CASMI), UK 08:50-09:10 Metabesity—What, Why and How Alexander Fleming, Executive Chairman and Founder, Kinexum, USA (Co-Chair) 09:10-09:50 It’s as Much About Economics as Science Joseph C. Cook, Jr., Former Chairman and CEO of Amylin, Group Vice President, Global Operations of Eli Lilly, USA 09:50-10:00 Overview of the Congress Lawrence Steinman, George A. Zimmermann Professor and Professor of Pediatrics, Stanford University, USA (Co-Chair)
10:00	Session II: Metabesity Targets
	Moderator: Alexander Fleming 10:00-10:25 Why Can’t I Prevent Obesity and Type 2 Diabetes? Philip Home, Professor of Diabetes Medicine, Newcastle University, UK
10:25	Coffee Break, Networking and Poster Viewing
10:55	Session II: Metabesity Targets (continued)
	11:00-11:20 Common Inflammatory Pathways Associated with Degenerative Disease Sir John Bell, Regius Professor of Medicine, Oxford University, UK 11:20-11:55 Exploiting Tumour Suppressive Mechanisms for Early Intervention in Cancer Ashok Venkitaraman, Ursula Zoellner Professor of Cancer Research, University of Cambridge, and Director of the Medical Research Council (MRC) Cancer Unit, UK 11:55-12:20 NAD Metabolism and Aging Eric Verdin, Buck Institute for Research on Aging, California, USA 12:20-12:30 Panel Discussion
12:30	Lunch Break, Networking and Poster Viewing
13:30	Session III: Approaches to Metabesity
	Moderator: Lawrence Steinman 13:30-13:50 Neuroinflammation - Using Big Data to Inform Clinical Practice Lars Fugger, Weatherall Institute of Molecular Medicine, Oxford, UK 13:50-14:10 Interactions between Genetic, Lifestyle/Environmental Risk Factors for Multiple Sclerosis Tomas Olsson, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden 14:10-14:30 Glucose Metabolism and Dementia Teresa Niccoli, University College London, UK 14:30-14:50 Metabesity and Dementia Paul M. Matthews, OBE, MD, DPil, FRCP, FMedSci, Imperial College London, UK 14:50-15:10 Loneliness and Metabesity? Lucy Rose, Former Director, Office of Training and Communications and Division of Drug Marketing, Advertising and Communications, Center for Drug Evaluation and Research (CDER) at the FDA, USA
15:10	Coffee Break, Networking and Poster Viewing
15:40	Session III: Approaches to Metabesity (continued)
	15:40-16:00 What Have We Learned from the Diabetes Prevention Trials? Itamar Raz, Head, Israeli National Council of Diabetes, Israel 16:00-16:20 Vitamin D and Obesity Jenny Gunton, Chair of Medicine, University of Sydney, Westmead Hospital, Australia 16:20-16:30 Panel Discussion
16:30	Session IV: Regulatory Considerations
	16:30-17:00 Panel: What to Expect from Regulatory Agencies, and What Could They Do? Alexander Fleming (former FDA official) Lucy Rose (former FDA official) Brian Harvey (former FDA official) Philip Home (former advisor to MHRA, EMA, NICE, FDA)17:00-17:30 Moderated Discussion: So What? A Look Ahead to Day 2 Ed Saltzman, Founder and Executive Chairman, Defined Health, USA
17:30	End of Day One

Tuesday, 31 October

07:00	Registration
08:00	Session V: Metabesity Interventions in Development
	Moderator: Brian Harvey 08:00-08:25 Qualifying Clinical Candidates for Anti-Aging Interventions Nir Barzilai, Albert Einstein College of Medicine, NY, USA 08:25-08:50 Targeting Aging with Metformin - Proof of Concept Steve Kritchevsky, Wake Forest Baptist Medical Center, Winston-Salem, USA 08:50-09:15 Hepatic Steatosis: What Do NASH Trials Teach Us? Brian Harvey, Executive Vice President, Scientific and Regulatory Affairs at the non-profit Global Liver Institute, USA 09:15-09:45 Before Pills: Prevention through Digital Health Stephanie Tilenius, Co-Founder and CEO, Vida Health, USA
09:45	Session VI: Who Pays? And How?
	09:45-10:30 Conversation: Implications of Metabesity for Healthcare SystemsGillian Leng, Deputy Chief Executive, National Institute for Health and Care Excellence (NICE), UK and Barry Straube, Former Chief Medical Officer for the Center for Medicare and Medicaid Services (CMS), USA
10:30	Coffee Break, Networking and Poster Viewing
11:00	Session VII: Industry and Capital Markets
	Moderator: Ed Saltzman11:00-12:00 Panel: The View from Industry New Business Models Joseph C. Cook, Jr., Executive Chairman and President, NuSirt BioPharma, USA How Does Big Pharma See This? (to be announced) 12:00-12:30 Metabesity and Capital Markets (to be announced)
12:30	Lunch Break, Networking and Poster Viewing
13:30	Session VIII: Ethics and "Patients"
	Moderator: To be Announced 13:30-13:50 Ethics for an Age of "Metabesity" Joshua Hordern, Associate Professor of Christian Ethics, University of Oxford, UK13:50-14:20 Voice of Patients and Their Advocates Payal Marathe, Senior Associate, Close Concerns, USA 14:20-14:40 Voice of the Would-Be Non-Patient Julia Manning, Founding Director, 2020health, UK (Co-Chair) 14:40-15:00 Panel Discussion
15:00	Coffee Break, Networking and Poster Viewing
15:30	Session IX: Where Do We Go from Here
	Moderators: Julia Manning and Thomas SeohMultilogue: Take Homes and Next Steps Speakers and Delegates
17:00	End of Congress